ROSETTA INPHARMATICS INC
10-Q, EX-27.1, 2000-10-26
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: ROSETTA INPHARMATICS INC, 10-Q, 2000-10-26
Next: NUVEEN MONEY MARKET TRUST, NSAR-A, 2000-10-26



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM UNAUDITED
FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2000 AND FOR THE NINE MONTHS ENDED AND
IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                         118,210
<SECURITIES>                                    40,456
<RECEIVABLES>                                    1,144
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               162,492
<PP&E>                                           9,538
<DEPRECIATION>                                   2,678
<TOTAL-ASSETS>                                 186,119
<CURRENT-LIABILITIES>                            7,558
<BONDS>                                            612
                                0
                                          0
<COMMON>                                            32
<OTHER-SE>                                     173,600
<TOTAL-LIABILITY-AND-EQUITY>                   186,119
<SALES>                                              0
<TOTAL-REVENUES>                                 4,907
<CGS>                                                0
<TOTAL-COSTS>                                   33,684
<OTHER-EXPENSES>                                    68
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 191
<INCOME-PRETAX>                               (25,938)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (25,938)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (25,938)
<EPS-BASIC>                                     (3.05)
<EPS-DILUTED>                                   (3.05)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission